Cingulate (CING) Set to Release Earnings on Thursday

Cingulate (NASDAQ:CING) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.48) per share and revenue of $0.54 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Cingulate (NASDAQ:CING) last posted its earnings results on Thursday, August 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.18. On average, analysts expect Cingulate to post ($2.19) EPS for the current fiscal year and ($0.88) EPS for the next fiscal year.

Cingulate Stock Performance

Shares of Cingulate stock opened at $4.56 on Thursday. The business has a 50-day moving average of $4.97 and a two-hundred day moving average of $5.43. Cingulate has a 1 year low of $3.16 and a 1 year high of $11.89.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Weiss Ratings upgraded Cingulate from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 20th. Roth Capital set a $9.00 target price on Cingulate and gave the stock a “buy” rating in a research note on Sunday, August 23rd. Finally, Wall Street Zen upgraded shares of Cingulate from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.00.

Cingulate Company Profile

Cingulate Inc (NASDAQ:CING) is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company’s lead programs are based on its proprietary Precision Timed Release (PTR) drug-delivery platform, which is designed to provide controlled, timed releases of medication from a single oral dose.

Cingulate’s primary product candidate is CTx-1301, an extended-release formulation of dexmethylphenidate intended to provide all-day ADHD symptom control through multiple releases of the active ingredient.